pharm chapter 10 2008
DESCRIPTION
Drugs for Psychoses & Degenerative Diseases of the Nervous System Chapter 10 Introduction •Disorders associated with emotional, unusual, or bizarre feelings are among the leading causes of mental health problems. •Will cover behavioral/emotional disorders, mood disorders, and psychoses.TRANSCRIPT
![Page 1: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/1.jpg)
Drugs for Psychoses & Degenerative Diseases of the Nervous System
Chapter 10
![Page 2: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/2.jpg)
Introduction • Disorders associated
with emotional, unusual, or bizarre feelings are among the leading causes of mental health problems.
• Will cover behavioral/emotional disorders, mood disorders, and psychoses.
![Page 3: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/3.jpg)
Introduction • Most psychoses have
no identifiable cause and require long-term drug therapy.
• Patients with psychoses often cannot tell what is and is not real.
• Delusions, hallucinations, illusions, disorganized behavior, difficulty relating to others.
![Page 4: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/4.jpg)
Introduction •People with
psychosis are usually unable to function normally in society without lifelong drug therapy and ongoing visits with a healthcare provider.
![Page 5: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/5.jpg)
Mood Stabilizers • is the major psychosis
—characterized by abnormal thoughts and thought processes, disordered communication, withdrawal from other people and the outside environment, and a high risk for suicide.
![Page 6: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/6.jpg)
Mood Stabilizers •Characteristics
include: pg. 150 bulleted▫Delusions—false beliefs
or ideas▫Hallucinations—
experiencing something that is not really there.
▫Paranoia—feeling that someone is “out to get” one
![Page 7: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/7.jpg)
Mood Stabilizers • Several theories—positive and
negative symptoms help determine type of medication.
• Positive—those that add on to normal behavior—hallucinations, delusions, and a disorganized thought or speech pattern.
• Negative—those that subtract from normal behavior—lack of interest, motivation, or responsiveness, and lack of pleasure in daily life
![Page 8: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/8.jpg)
Mood Stabilizers •Antipsychotic
medication attempts to stabilize client with psychoses—AKA neuroleptics
•Conventional antipsychotics
•Atypical antipsychotics
![Page 9: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/9.jpg)
Mood Stabilizers • Conventional antipsychotic—
Table 10.1 pg. 152.• More effective in treating positive
symptoms of schizophrenia• Extrapyramidal side effects—
reduce dose may go away• Neuroleptic malignant syndrome-
rare; with dosages; can be fatal• DP—chlorpromazine (Thorazine)
pg. 154
![Page 10: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/10.jpg)
Mood Stabilizers • Atypical
antipsychotics—Table 10.4 pg. 158
• Treat both positive and negative symptoms of schizophrenia
• Fewer side effects• DP—clorozapine
(Clozaril) pg. 158.
![Page 11: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/11.jpg)
Parkinsons Disease •Parkinsons disease
is a degenerative disorder of the CNS caused by death of neurons that produce the brain neurotransmitter dopamine.
•It is characterized by disturbances of muscle movement.
![Page 12: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/12.jpg)
Parkinsons Disease •Symptoms
include:▫Tremors▫Muscle rigidity▫Bradykinesia▫Postural instability
![Page 13: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/13.jpg)
Parkinsons Disease •Symptoms of
Parkinson’s disease result from dysfunction of Dopamine neurotransmitter between various parts of the brain.
![Page 14: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/14.jpg)
Parkinsons Disease •Drug therapy for
Parkinson’s symptoms focuses mainly on dopamine and acetylcholine.
•Two major drug therapies are levodopa (Larodopa) and benztropine (Cogentin)
![Page 15: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/15.jpg)
Parkinsons Disease •Extrapyramidal
symptoms (EPS)—symptoms where muscles become very rigid because of over-medication with anti-psychotics or by lack of dopamine function in the corpus striatium.
![Page 16: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/16.jpg)
Parkinsons Disease •If Extrapyramidal
symptoms occur in the health care facility—Benadryl may be given
•If untreated can be fatal
![Page 17: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/17.jpg)
Parkinsons Disease • Tardive dyskinesia—a movement disorder
often causing involuntary lip and tongue movements and less frequently causing involuntary movements of the trunk and extremities, is observed in client’s who have been given anti-psychotic drugs for an extended length of time.
• Anticholinergic med’s prescribed concurrently with anti-psychotics to discourage development of tardive dyskinesia or to treat it once it develops.
![Page 18: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/18.jpg)
Parkinsons Disease •Dopaminergic
drugs –table 10.6 pg. 161▫Replace dopamine
or increase its action in the brain
▫Drug Profile Levodopa pg. 163.
![Page 19: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/19.jpg)
Parkinsons Disease •Cholinergic
blocking drugs—Table 10.7 pg. 164▫Block effect of
acetylcholine in CNS
▫Used in clients who cannot tolerate levodopa
▫Drug profile—benztropine (Cogentin)– pg. 164
![Page 20: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/20.jpg)
Alzheimers’s Disease • Alzheimer’s Disease
▫ Diagnosis only on autopsy—amyloid plaques & neurofibrillary tangles present
▫ Loss of cholinergic brain function especially in the hippocampus—an area of the brain responsible for learning and memory.
▫ Symptoms pg. 165
![Page 21: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/21.jpg)
Dementia• Dementia is a progressive
and permanent loss of brain function.
• Two common types of dementia are Alzheimer’s disease and vascular dementia.
• Restorative drug therapies for dementia mainly focus on Alzheimer’s disease because this is the most common type of dementia.
![Page 22: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/22.jpg)
Alzheimer’s Disease • Alzheimers drugs
Table 10.8 pg. 166.• Current medications
result in minor improvement of symptoms
• Attempt to slow memory loss
• Enhance action of acetylcholine in brain
• Drug profile—Aricept pg. 167.
![Page 23: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/23.jpg)
Multiple Sclerosis • MS is an autoimmune
disorder of the CNS.• Antibodies target and
slowly destroy tissues in the brain and spinal cord.
• As tissues are damaged, inflammation of nervous tissue causes demyelination, or the loss of myelin, a fatty material that acts as a protective insulator of nerve fibers.
![Page 24: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/24.jpg)
Multiple Sclerosis • Gradually disrupts the
ability of the nerves to conduct electrical impulses to and from the brain.
• Common s/s: fatigue, heat sensitivity, pain, spasticity (muscle cramps and spasms), cognitive problems, balance and coordination problems, and bowel and bladder symptoms.
![Page 25: PHARM CHAPTER 10 2008](https://reader034.vdocument.in/reader034/viewer/2022042718/568bd7171a28ab20349e6fc0/html5/thumbnails/25.jpg)
Multiple Sclerosis • Two basic strategies
for treating MS.• One approach
attempts to reduce inflammation and prevent attacks on the nervous system.
• The other strategy emphasizes treatments to relieve symptoms.
• Drugs used for MS Table 10.9 pg. 169